Targeting influenza virus neuraminidase—a new strategy for antiviral therapy

Influenza virus infection causes substantial morbidity and mortality worldwide, but current options for control are limited. Although major advances have been made in antiviral therapy of infections such as herpes and HIV, a `magic bullet' for influenza has proved elusive. The influenza neurami...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 1998-10, Vol.3 (10), p.448-456
Main Authors: Oxford, John S, Lambkin, Robert
Format: Article
Language:English
Subjects:
antiviral therapy
drug development
Herpesvirus
Human immunodeficiency virus 1
Influenza A virus
neuramidase inhibitor
oral influenza treatment
Ro640769 (GS4104)
targeted drug design
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Influenza virus infection causes substantial morbidity and mortality worldwide, but current options for control are limited. Although major advances have been made in antiviral therapy of infections such as herpes and HIV, a `magic bullet' for influenza has proved elusive. The influenza neuraminidase enzyme is an attractive target for antiviral intervention, its active site is antigenically conserved in all clinically relevant strains and is critical to viral replication. The authors consider the subject of neuraminidase inhibition and discuss, in particular, the development of the oral agent Ro640796 (GS4104). The concept of neuraminidase inhibition is likely to lead to a major breakthrough in the control of influenza.
ISSN:1359-6446
1878-5832
DOI:10.1016/S1359-6446(98)01241-0